会议报道

订阅

MedSci主页 / 所有栏目 / 会议报道

比较奥沙利铂联合5-氟尿嘧啶/亚叶酸钙（FOLFOX4方案）或阿霉素治疗国人晚期肝细胞癌的有效性和安全性的Ⅲ期临床研究

2010-09-19 MedSci原创 MedSci原创

肝癌秦叔逵研究
关注

　　报告者：南京八一医院全军肿瘤中心秦叔逵  　　时间：9 月17 日09:30～09:50  　　地点：16 区3 层1 号多功能厅 　　在乙型肝炎高发的中国，肝细胞癌（HCC）分别位列常见恶性肿瘤的第3位和主要癌症死亡的第2位。系统性化疗常常用于治疗晚期HCC，但迄今为止尚无标准的药物或方案被证实有生存获益。奥沙利铂（

　　报告者：南京八一医院全军肿瘤中心秦叔逵 

　　时间：9 月17 日09:30～09:50 

　　地点：16 区3 层1 号多功能厅

　　在乙型肝炎高发的中国，肝细胞癌（HCC）分别位列常见恶性肿瘤的第3位和主要癌症死亡的第2位。系统性化疗常常用于治疗晚期HCC，但迄今为止尚无标准的药物或方案被证实有生存获益。奥沙利铂（OXA）是第3代新型铂类药物。近年来，若干项含OXA方案治疗晚期HCC的Ⅱ期研究均显示出一定的临床疗效，由此鼓舞我们继续进行深入研究。 

　　本研究为开放、随机、多中心Ⅲ期国际临床研究（EACH 研究），中国大陆和台湾地区、韩国和泰国38家中心共计入组371例不适于进行根治性切除术或局部治疗的局部晚期或转移性HCC患者，其中中国大陆入组259例患者（70%）。患者以1：1的比例随机进入FOLFOX 4组或多柔比星（阿霉素，ADM）组。研究主要目的旨在确定FOLFOX4方案较阿霉素能否提高OS，次要目的有PFS、有效率（RR）及疾病控制率（DCR）和安全性。 

　　亚组分析数据显示，与ADM相比，FOLFOX4 显著提高了中国的晚期HCC患者的mOS、mPFS、RR 和DCR。FOLFOX 4 治疗耐受性好，安全性高，不良反应易于处理。该研究首次证实含OXA联合方案的系统化疗能够延长晚期HCC患者的生存时间。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-19 xjy02

    #肝细胞#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-09-01 ms3153534357578991

    #铂#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-28 qingting

    #细胞癌#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 hb2008ye

    #晚期肝细胞癌#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 linlin2314

    #FOLFOX#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 12498761m58暂无昵称

    #5-氟尿嘧啶#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 dinorsor527

    #Ⅲ期临床#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1863174, encodeId=c43a18631e48c, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sun Sep 19 20:53:00 CST 2010, time=2010-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737427, encodeId=cdf11e374278d, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Thu Sep 01 21:53:00 CST 2011, time=2011-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978295, encodeId=40e919e82951b, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Sep 28 20:53:00 CST 2010, time=2010-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368171, encodeId=aab913681e1f1, content=<a href='/topic/show?id=a92e59863f2' target=_blank style='color:#2F92EE;'>#晚期肝细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59863, encryptionId=a92e59863f2, topicName=晚期肝细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455437, encodeId=46c9145543e41, content=<a href='/topic/show?id=d0cee572e9' target=_blank style='color:#2F92EE;'>#FOLFOX#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7572, encryptionId=d0cee572e9, topicName=FOLFOX)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12f25658567, createdName=linlin2314, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479572, encodeId=c1f314e957295, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495843, encodeId=5a28149584311, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542838, encodeId=7aaa1542838d2, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Tue Sep 21 10:53:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 12498710m15暂无昵称

    #氟尿嘧啶#

    0